Human leukemogens, including alkylating chemotherapeutic agents and benzene, enhance granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent proliferation of human CD34 þ bone marrow (BM) cells. The extracellular signal-regulated kinase (ERK) pathway plays an important role in GM-CSF-dependent proliferation and also has been implicated in the pathogenesis of acute myelogenous leukemia. Therefore, we investigated the effects of the benzene metabolite, hydroquinone (HQ), on alterations in the GM-CSF signaling pathway in TF-1 erythroleukemia cells and human CD34 þ BM cells. HQ treatment in TF-1 cells results in a strong proliferative response that is dependent on ERK activation and GM-CSF production. HQ also induces ERK-dependent AP-1 activation with concomitant increased transcriptional activity of AP-1 reporter gene. However, the kinetics of ERK activation are different between rhGM-CSF and HQ in TF-1 cells: rhGM-CSF results in immediate activation of ERK, whereas HQ activation of ERK is delayed. Further, HQ and rhGM-CSF together produce an immediate increase in ERK phosphorylation, which is sustained for over 48 h. HQ also stimulates colony formation, AP-1 DNA binding and GM-CSF production in human CD34 þ BM cells. These results suggest that HQ stimulates proliferation via activation of ERK/AP-1 and is at least partially mediated via the production of GM-CSF.
Introduction
Acute myelogenous leukemia (AML) developing secondary to exposure to alkylating chemotherapeutic agents or chronic exposure to benzene (BZ) frequently progresses from initial BM injury or hypoplasia to myelodysplastic syndrome (sMDS) and sAML. [1] [2] [3] A variety of studies suggest that the cell of origin in sMDS/sAML is a multilineage progenitor cell capable of differentiation to myeloid and erythroid cells (ie colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM)). [1] [2] [3] A variety of human leukemogens, including cyclophosphamide, melphalan and BZ, result in enhanced CFU response, following exposure both in vitro and in vivo, which is dependent upon hematopoietic cytokines, such as GM-CSF. [3] [4] [5] Increases in granulocyte CFU have been observed in mice within 2 h of exposure to BZ in vivo, apparently at the expense of erythroid CFU. [4] [5] [6] We have also observed clonogenic enhancement in human CD34 þ BM cells treated in vitro with the BZ metabolite, hydroquinone (HQ), and then cultured in the presence of exogenous rhGM-CSF. 7, 8 Cell proliferation is a wellrecognized risk factor in carcinogenesis; cell division resulting in a number of chemical and mechanical stresses that increase the likelihood of acquiring structural genomic changes. Individual malignancies, particularly hematopoietic and lymphoid cancers, often exhibit unique patterns or signatures of clonal lesions that are thought to play important roles in either the initiation or pathogenesis of these individual diseases. Nevertheless, little is actually known about the orchestration of the earliest events that result in the evolution of cell-and diseasetype-specific clonal lesions in human leukemogenesis. We hypothesize that chemicals with leukemogenic potential can mimic or synergize with molecular mediators of the GM-CSF receptor mitogen-signaling pathway resulting in increased clonal proliferation in the target cell population that constitutes the origin for sMDS and sAML.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling is mediated via a variety of kinase cascades (eg MAPK, Janus kinase (JAK)/signal transducers and activators of transcription 5 (Stat5), protein kinase C (PKC), phosphatidylinositide 3 (PI3) Kinase). 9, 10 However, cytokine-mediated stimulation of these kinase pathways ultimately results in AP-1 activation. 11 In particular, the MAPK (eg ERK, Jun N-terminal kinase (JNK) and p38 kinase) have been demonstrated to play important roles in the control of both cellular growth and cytokine production. 12, 13 ERK is the best characterized pathway for GM-CSF-induced proliferation resulting from the activation of AP-1, and constitutive activation of ERK is frequently observed in leukemia cells. 11, 12, 14 Therefore, we decided to characterize the molecular events occurring in the ERK pathway following treatment of TF-1 cells or primary human CD34 þ cells with HQ.
TF-1 cells exhibit a strong proliferative response to GM-CSF that is thought to be mediated through the Ras/Raf/ MEK/ERK pathway. [15] [16] [17] We used TF-1 cells to examine the mechanisms of HQ-induced alterations in clonogenic response associated with GM-CSF-dependent signal transduction and compared these results with those obtained using primary human CD34 þ BM cells. Our results show that HQ stimulates proliferation of TF-1 cells via activation of the ERK/AP-1 signalling pathway together with concomitant increases in GM-CSF production and clonogenic response. In contrast, HQ enhancement of CFU response in human CD34 þ BM cells is dependent on the addition of exogenous rhGM-CSF, 7, 8 but similarly is accompanied by AP-1 activation and an increase in GM-CSF production. Taken collectively, these studies suggest that HQ exerts many of its hematopoietic effects via alterations in the GM-CSF signaling pathway.
Materials and methods

CD34 þ /CD19À cell purification
Cell purification was performed as previously described. 18 All protocols were approved by the University of Colorado Health Sciences Center Internal Review Board. BM aspirates were obtained from normal adult volunteers after informed consent. Briefly, mononuclear cells were isolated using Lymphocyte Separation Medium (Cellgro, Herndon, VA, USA) and CD34 þ / CD19À cells were purified using a high magnetic gradient Mini-MACS purification system (Miltenyi, Sunnyvale, CA, USA). Our technique included a combination of a depletion column (CD19 þ ) followed by a positive selection column (CD34 þ ). The purity of isolated cells (495% CD34 þ /CD19À) was determined using flow cytometric analysis (Coulter Electronics, Hialeah, FL, USA).
Cell culture and treatment
TF-1 cells, a growth factor-dependent human erythroleukemia cell line 15 originally obtained from ATCC (Manassas, VA, USA), were maintained in complete RPMI-1640 media (Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal calf serum, 100 mg/ml streptomycin, 100 U/ml penicillin, and 2 mmol/l L-glutamine in the presence of optimal concentrations of rhGM-CSF (5 ng/ml) (Immunex, Seattle, WA, USA) at 371C, in humidified air containing 5% CO 2 . Experimental TF-1 cells were deprived of rhGM-CSF overnight (16 h) followed by chemical or growth factor treatment. HQ (Sigma) was dissolved in phosphate-buffered saline (PBS, Gibco BRL) and added to the cells to yield the final concentrations indicated. Cells were cultured for various times as indicated in the results. For the study of ERK activation, rhGM-CSF-deprived TF-1 cells were preincubated with MEK 1 inhibitor, PD98059 (BioLabs, Beverly, MA, USA), at various concentrations for 30 min prior to HQ or rhGM-CSF treatment. Cells were then harvested at specific time points for each experiment. Purified CD34 þ cells were resuspended in complete RPMI-1640 media followed by 16 h chemical or growth factor treatment.
Electrophoretic mobility shift assay (EMSA)
TF-1 cells and/or purified CD34 þ /CD19À cells were treated as described above and cell extracts were prepared as previously described. 18 Protein concentrations were determined using a BCA protein kit (Piece, Rockford, IL, USA) and the protein was frozen at À801C until future analysis. AP-1 consensus sequences 5 0 TCC GCT TGA TGA GTC AGC CGG AA 3 0 and 5 0 TCT TCC GGC TGA CTC ATC AAG CG 3 0 were annealed and labeled as previously described.
19 Protein (4-6 mg) was incubated on ice for 10 min with 1 mg dI-dC, 4 ml binding buffer (20 mmol/l HEPES (pH 7.9), 40 mmol/l KCl, 10% glycerol, 0.05 mmol/l EDTA, 1.6 mmol/l MgCl 2 ), 1 mmol/l DTT, and deionized water for a total volume of 19 ml. Next, 1 ml of 32 P-labeled probe (B50 000 cpm) was added and the binding reaction was continued for 30 min at 221C. For supershift samples, appropriate specific antibodies against Fos family (c-Fos , Fos B, Fra1, Fra2) and Jun family (phospho-c-Jun, Jun D, Jun B, c-Jun) (Santa Cruz, CA, USA) were added to the binding buffer before protein addition. After complex formation, 2 ml of loading buffer (250 mmol/l Tris HCL (pH 7.5), 0.2% bromophenol blue, 0.2% xylene cyanol, 40% glycerol) was added to the DNA-protein complexes, and the samples were analyzed by electrophoresis on a prerun 6% polyacrylamide gel. The gels were dried and exposed at À801C to Fuji x-ray film (Tokyo, Japan).
Western blot of ERK kinase activity
Treatment was performed and the proteins were prepared as described above. Approximately 50 mg of protein was analyzed by SDS polyacrylamide gel electrophoresis and transferred to Nitrocellulose membrane (Bio-Rad, CA, USA). The membranes were probed with specific phospho-p44/p42 antibody (Bio-Lab, CA PhosphoPlus p44/42 MAP kinase antibody Kit), which detects the activated phosphorylated forms of ERK kinase (ERK1 and ERK2). The same membranes were stripped and reprobed with nonphospho-p44/42 antibody, which detects total ERK kinase (phosphorylation-state independent) as a control for sample variation. Western analysis of membranes was performed using a Super Signal West Pico Trail Kit (Pierce, IL, USA) followed by exposure of ECL-film (Boehringer Mannheim, IN, USA).
Transfection assay
TF-1 cells were deprived of rhGM-CSF for 4-6 h and resuspended in hypoosmolar electroporation buffer (Eppendorf, Hamburg, Germany) to a final concentration of 1 Â 10 6 cells/ ml. Cells were cotransfected with an experimental reporter gene, 4AP-1, and/or a control reporter gene, pRL-TK, by electroporation at 400 V and a charging time of 100 ms, using a Multiporater (Eppendorf, Hamburg, Germany). The 4AP-1 gene was constructed by inserting four copies of AP-1 sites (5 0 -GAT CGA TCC GGC TGA CTC ATC ACT AG -3 0 ) into a pGL3 vector driving the firefly luciferase gene (a gift from Dr Vasilis Vasiliou). The pRL-TK construct consists of the Renilla Luciferase gene under the control of the TK promoter (Promega, Madison WI, USA). Cells were treated 24 h with HQ or rhGM-CSF, washed and lysed in 50 ml of Passive Lysis Buffer (Promega). Cell lysates (10 ml) were analyzed for both Firefly (F) and Renilla (R) luciferase activity using the Dual-Luciferase Assay System (Promega). Each experiment was performed in duplicate, and the average of the two expressed as relative luciferase activity (F/R). 
Colony-forming (CFU) assays
CFU assays were performed as previously described. 8 Briefly, chemical-and/or growth factor-treated TF-1 cells were plated in 35-mm culture dishes at 8 Â 10 3 cells/ml in Iscove's modified Dulbecco's medium (10% fetal bovine serum, 100 mg/ml streptomycin, 100 U/ml penicillin, 2 mmol/l L-glutamine, 50 mmol/l 2-mercaptoethanol, 1.2% (wt/vol) methyl cellulose) (Gibco, Grand Island, NY, USA). Cultures were maintained at 371C in 5% CO 2 and colonies counted on day 14. A cluster of cells numbering greater than 50 was scored as a colony. Five plates were scored for each treatment group, and significant differences (Po0.05) in colonies/culture observed between control and treated groups were determined using the Student's t-test, and the results expressed as the mean71 standard error of the mean (s.e.m.).
Determination of [GM-CSF] in culture supernatants
Culture supernatants were analyzed for [GM-CSF] using a Human GM-CSF Immunoassay Kit (BioErgonomics, St Paul, MN, USA) following manufacture instruction. Briefly, supernatants were removed from cell cultures at 2 h, 4 h and/or 16 h post chemical and/or growth factor treatment and mixed with GM-CSF-specific capture beads and incubated for 1 h at room temperature. Capture beads were removed via centrifugation, washed and resuspended in buffer containing a GM-CSF reporter antibody, which is conjugated with phycoerythrin. Supernatant [GM-CSF] was then determined using a Coulter Epics XL Cytometer calibrated against a standard curve for known concentrations of GM-CSF. These results were confirmed using a GM-CSF neutralizing antibody.
GM-CSF neutralizing antibody assay
Dependence of TF-1 cell proliferation on GM-CSF production was determined using a GM-CSF neutralizing antibody, which is selected for its ability to neutralize the biological activity of both rhGM-CSF and natural human GM-CSF (R&D Systems, Minneapolis, MN, USA). TF-1 cells were pretreated with either control goat IgG (10 mg/ml) or increasing doses of GM-CSF neutralizing antibody for 30 min prior to the addition of either 10 mM HQ or 0.5 ng/ml rhGM-CSF and then the incubation was continued for an additional 12 h followed by [ 3 H]thymidine incorporation assay performed as described above.
All experiments described in this study were repeated at least three separate times.
Results
HQ stimulates proliferation and colony formation in TF-1 cells
A variety of hematotoxic alkylating agents or their metabolites stimulate GM-CSF-dependent proliferation and colony formation in human CD34 þ BM cells. In order to determine whether TF-1 cells respond in a manner similar to primary BM cells, we examined the effects of rhGM-CSF and HQ on proliferation and CFU in TF-1 cells in culture. Overnight, rhGM-CSF-deprived TF-1 cells were incubated for 16 h with predetermined optimal concentrations of either HQ (10 mM) or rhGM-CSF (5 ng/ml) and assayed for proliferation ( Figure 1a ) and CFU (Figure 1b) . Treatment of TF-1 cells with either rhGM-CSF or HQ produces significant increases in proliferation and CFU in TF-1 cells. Increases in cytokine-dependent CFU are analogous to increases in the recruitment of individual cell clones to undergo proliferation and differentiation.
HQ activates ERK kinase in TF-1 cells
We measured ERK activation at specific time points posttreatment. TF-1 cells were treated with HQ, rhGM-CSF or HQ þ rhGM-CSF, and ERK phosphorylation was measured at various time points over a 48 h period. Since ERK kinase consists of two protein kinases (ERK44 and ERK42) that are encoded by Erk1/Erk2, full enzymatic activation of ERK requires phosphorylation on specific tyrosine and threonine sites. 20, 21 Treatment with HQ or rhGM-CSF results in activation of ERK in a timedependent manner (Figure 2a ). ERK is activated by 4 h, maximal at 12 h and is visible at 48 h following treatment with HQ. However, rhGM-CSF treatment results in immediate ERK activation that peaks at 10 min and progressively declines over 24 h. Further, treatment of TF-1 cells with HQ and rhGM-CSF together results in immediate activation of ERK, which is sustained at high levels for 12 h and remains demonstrable at 48 h (Figure 2a) . In order to confirm the dose dependence of HQ-induced ERK activation, TF-1 cells were treated with increasing doses of HQ and pERK measured at 16 h (Figure 2b ). In order to determine the specificity of ERK activation, TF-1 cells were pretreated with increasing doses of the MEK1 inhibitor, PD98058, then followed by treatment with 10 mM HQ. PD98058 is a selective inhibitor of the ERK kinase cascade. 20, 21 PD98058 binds tightly to inactive MEK1 and prevents its activation by upstream signals such as Raf. TF-1 cells pretreated with PD98058 exhibit a dose-dependent inhibition of HQ-induced activation of ERK kinase (Figure 2c ). ERK protein Figure 2 HQ induces a time-and concentration-dependent activation of ERK in TF-1 cells measured by Western Blot analysis using anti-phospho-ERK antibody. (a) rhGM-CSF-deprived TF-1 cells were treated with either rhGM-CSF (5 ng/ml), HQ (10 mM) or both, and whole-cell extracts were prepared at specific time points. (b) Cells were treated with increasing concentrations of HQ, and ERK was measured at 16 h. (c) Cells were pretreated with increasing concentrations of the MEK1 inhibitor, PD98059, followed by treatment with HQ or rhGM-CSF for 16 h. Total ERK protein was detected with nonphoshorylated-ERK antibody. Phosphorylated ERK (pERK) and nonphosphorylated ERK (ERK) were used as positive and negative controls, respectively. (M ¼ size marker; C ¼ control cells).
Figure 3
The MEK1 inhibitor, PD98059, abrogates HQ-induced proliferation and CFU in TF-1 cells. TF-1 cells were deprived of rhGM-CSF and preincubated with increasing doses of PD98059 for 30 min, followed by the addition of HQ (10 mM) or rhGM-CSF (5 ng/ml) and incubated for 16 h. TF-1 cells were (a) pulsed with [ levels do not appear to be affected by treatment with rhGM-CSF, HQ and/or PD98059. These results suggest that HQ-induced activation of ERK occurs via phosphorylation, and that induction of ERK protein is not involved in the pathway of ERK activation.
HQ-induced proliferation and colony formation in TF-1 cells is dependent on activation of ERK kinase
In order to determine whether HQ-induced cell proliferation and enhanced CFU was dependent on activation of the ERK kinase pathway, TF-1 cells were preincubated with increasing doses of PD98059 prior to incubation with either HQ or rhGM-CSF. TF-1 cells, pretreated with PD98059, exhibit a dosedependent inhibition of both proliferation (Figure 3a) and CFU (Figure 3b) induced by HQ. These results demonstrate that activation of ERK pathway is required for cell proliferation and for colony formation by HQ in TF-1 cells.
HQ induces ERK-dependent AP-1 DNA binding in TF-1 cells
The ERK pathway is known to be a major activator for AP-1 in many cells. 16, 22 Therefore, we investigated whether HQinduced activation of ERK coincides with AP-1 DNA binding in TF-1 cells. TF-1 cells were deprived of rhGM-CSF and then treated with either rhGM-CSF or increasing concentrations of HQ for 16 h. Treatment with HQ results in a concentrationdependent increase in AP-1 DNA binding (Figure 4a ) that is inhibited by pretreatment with the MEK1 inhibitor, PD98059 (Figure 4b ). The specificity of AP-1 DNA binding was demon- 
HQ transactivates an AP-1-dependent reporter gene in TF-1 cells
In order to determine whether HQ-induced AP-1 DNA binding results in an increase in transcriptional activation of an AP-1-dependent gene, we transfected TF-1 cells with an AP-1-dependent reporter gene that was generated by inserting four copies of AP-1 (4AP-1) binding sites into a pGL3 vector. TF-1 cells, deprived of rhGM-CSF, were transfected, exposed to rhGM-CSF (5 ng/ml) or increasing concentrations of HQ, and the luciferase activity was determined after 24 h as described in the materials and methods. HQ induced a concentration-dependent increase in activation of the reporter gene 4AP-1 ( Figure 5 ). Although rhGM-CSF treatment produced a strong AP-1 DNA binding response, it resulted in a smaller 4AP-1 reporter gene activation signal than HQ. Taken together, these results demonstrate a strong correlation between HQ-induced AP-1 DNA binding and activation of the AP-1 promoter in TF-1 cells independent of cellular stimulation with rhGM-CSF.
HQ produces an increase in GM-CSF production in TF-1 cells
One of the many known activities of GM-CSF is the stimulation of its own production. Therefore, we hypothesized that HQinduced activation of the GM-CSF signaling pathway and enhanced cell proliferation might be mediated via the production of GM-CSF. rhGM-CSF-deprived TF-1 cells were treated with increasing concentrations of HQ and [GM-CSF] measured in culture supernatants at the indicated time points. HQ treatment revealed no detectable [GM-CSF] at both 2 and 4 h (data not shown), but results in a dose-dependent increase in [GM-CSF] at 16 h (Figure 6a) . Independently, pretreatment of TF-1 cells with neutralizing anti-GM-CSF antibody abrogated HQ-induced proliferation (Figure 6b ).
HQ activates AP-1 DNA binding and GM-CSF production in primary human CD34 þ BM cells Based on our results obtained using TF-1 cells, we evaluated AP-1 DNA binding and GM-CSF production in primary human CD34 þ /CD19À BM cells. Purified CD34 þ /CD19À cells were treated with HQ and then cultured in complete RPMI-1640 media supplemented with or without rhIL-3, Epo and SCF, in absence of rhGM-CSF for 16 h. Whole lysates were assayed for AP-1 activation by EMSA (Figure 7a ) and the supernatants were assayed for [GM-CSF] by ImmunoFlow beads (Figure 7b ). These results indicate that HQ stimulates AP-1 DNA binding and GM-CSF production in primary human CD34 þ BM cells that is comparable to that observed in TF-1 cells.
Discussion
GM-CSF is a pleiotropic hematopoietic cytokine that exerts multiple functions on hematopoietic progenitor cells (HPC) including proliferation, survival, differentiation and stimulation of its own production. 23, 24 Enhanced clonogenic response to GM-CSF is frequently observed in AML, 25, 26 and GM-CSFdependent proliferation and clonogenic response has been repeatedly demonstrated to be mediated via the Ras/Raf/ERK/ MAP kinase pathway. 12, 17 Independently, exposure to certain alkylating agents, including cyclophosphamide, melphalan and BZ, results in an enhanced clonogenic response (ie CFU) and proliferation of human CD34 þ BM cells that is also dependent on GM-CSF. 7, 8 Particularly for BZ, increases in granulocyte CFU have been observed in mice within 2 h of exposure in vivo, apparently at the expense of erythroid CFU. [4] [5] [6] Clonogenic enhancement is also observed in human CD34 þ BM cells treated in vitro for 30 min with the BZ metabolite, HQ, and cultured in the presence of exogenous rhGM-CSF. 7, 8 Activation of the ERK/MAP kinase pathway is also involved in GM-CSFinduced proliferation in TF-1 cells. 17 Therefore, we hypothesized that proliferation and clonal expansion of human CD34 þ multilineage hematopoietic progenitor cells might be mediated via activation of the ERK/MAP kinase pathway, and that TF-1 cells might serve as useful surrogates for primary CD34 þ BM cells in the study of the molecular mechanisms of chemicalinduced alteration in GM-CSF receptor signaling.
Previous studies have demonstrated that several alkylating chemotherapeutic agents share the ability to alter early events in the proliferation and recruitment of multilineage hematopoietic progenitor cells that are the cells of origin in sMDS and sAML. [1] [2] [3] The earliest common event appears to be enhanced clonogenic response of hematopoietic progenitor cells to GM-CSF. Pretreatment of human CD34 þ BM cells with HQ results in a 50-200% increase in the outgrowth of clones in response to rhGM-CSF. 7, 8 TF-1 cells exhibit a strong proliferative and clonogenic response to rhGM-CSF, which is similar to that previously characterized in CD34 þ HPC. 12, 15 Our findings demonstrate that in both CD34 þ and TF-1 cells, HQ results in an increase in AP-1-DNA binding and GM-CSF production. Our findings also show that rhGM-CSF and HQ activate AP-1 in TF-1 cells and that the HQ-induced activation of AP-1 is ERKspecific. However, the kinetics of ERK activation differ significantly between rhGM-CSF and HQ: rhGM-CSF-induced phosphorylation occurs within 10 min, and subsides over 24 h; HQ-induced phosphorylation is delayed, appears by 4 h and subsides over 48 h; phosphorylation induced by concomitant treatment with HQ and GM-CSF is immediate, sustained at high levels for 12 h and is clearly demonstrable at 48 h.
One explanation for these findings is that HQ alone modulates the GM-CSF signaling pathway, specifically involving the activation of ERK and AP-1, which ultimately results in GM-CSF production. TF-1 cells transfected with activated Raf exhibit activation of ERK and the secretion of an autocrine growth factor, which results in the abrogation of TF-1 cell cytokine dependency. 16 The cytokine, TNFa has also been demonstrated to stimulate proliferation in HU-3, MO7e and TF-1 cell lines by inducing the production of GM-CSF in these cells. 27 Independently, autocrine production of fibroblast growth factor has been demonstrated to induce delayed activation of ERK and AP-1 in human lung fibroblasts in response to TGFb1. 28 The response of TF-1 cells to HQ differs slightly from primary human CD34 þ BM cells: specifically HQ alone stimulates proliferation and CFU in TF-1 cells. However, HQ is unable to elicit a proliferative or clonogenic response in primary CD34 þ BM cells in the absence of concomitant stimulation with rhGM-CSF. 7, 8 Similar to TF-1 cells, HQ-induced increased clonogenic response in human CD34 þ BM cells is preceded by increased AP-1 DNA binding and appears to be dependent on the production of GM-CSF. One possible explanation is that, due to constitutive low-level production of GM-CSF, TF-1 cells may have a lower ERK activation threshold compared to primary CD34 þ BM cells. Alternatively, these results could be explained by HQ induction of another secondary mediator. Future studies will be needed to ascertain in greater detail the molecular mechanisms responsible for HQ-induced AP-1 activation, production of GM-CSF and their respective roles in proliferation and survival in CD34 þ BM cells. HQ activates AP-1 DNA binding and GM-CSF production in primary human CD34 þ cells. (a) Purified CD34 þ /CD19À cells were treated with HQ, cultured for 16 h and then whole-cell lysates were assayed for AP-1 activation by EMSA. One representative experiment is presented out of three independent experiments conducted. (b) Purified CD34 þ /CD19À cells were treated with increasing doses of HQ and cultured for 16 h in complete RPM-1640 media supplemented with IL-3, EPO and SCF, in absence of rhGM-CSF, and supernatants were assayed for [GM-CSF] by flow cytometry using ImmunoFlow beads (described in Figure 6 ). One representative experiment out of three independent experiments is shown.
